Finzati - Logo
BCRX logo

BioCryst Pharmaceuticals, Inc.

BCRX • Biotechnology
$9.83
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$2.61B
Growth
12.7%
Cash Flow
1/5
Trend
Volatile
Evidence
Stable or improving margins · 30.2%Positive revenue growth · 47.6%Positive free cash flow · 1.56Reasonable earnings multiple · 6.2Healthy liquidity · 2.06
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:57 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$9.83
Change0.00%
Shares Out265.17M
Market Cap$2.61B
Enterprise Value$2.25B
52W Range6.00 - 11.22
Beta0.54
P/E-6.78
P/S2.77
P/FCF7.29
EV/Sales2.40
EV/EBITDA-7.39

Investment DNA

How strong this company looks for long-term investors

83
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
80/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
93/100
Why this score▼
Stable or improving margins · 30.2%Positive revenue growth · 47.6%Positive free cash flow · 1.56Reasonable earnings multiple · 6.2Healthy liquidity · 2.06

Analyst view

Analyst sentiment and price target

BCRX
Analyst sentiment
Based on 29 analyst votes · 2026-09-04
93/100
Bullish
Bullish
25
Hold
4
Bearish
0
Price Target
2026-08-07
Low
$14.00
Mean
$20.00
Median
$17.00
High
$29.00

Company Overview

IPO: 3/4/1994
Industry: Biotechnology
P/B i: -13.74
Debt / Equity i: -4.01
Operating Margin: 38.98%
Net Margin: 30.16%
ROE i: -
ROIC: -

Financial Health

Score16 / 20
Debt / Equity: -4.01
Current Ratio: 2.06
Quick Ratio: 2.03
Status: Strong

Insider Transactions

Recent executive and insider activity

HEGGIE THERESA
Transaction: 06/11/2026
BUY
Change
+33,540
Price
$8.50
Filing
06/15/2026
Type
BUY
HEGGIE THERESA
Transaction: 06/11/2026
BUY
Change
+15,294
Price
Not reported
Filing
06/15/2026
Type
BUY
McKee Amy E
Transaction: 06/11/2026
BUY
Change
+33,540
Price
$8.50
Filing
06/15/2026
Type
BUY